BiotechTube

CTx-1301-Dexmethylphenidate 12.5 mg (titration only) + CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose) + CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose) + CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose) + Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

ADHD

Conditions

ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity, Attention Deficit Hyper Activity

Trial Timeline

Aug 1, 2023 → Feb 29, 2024

NCT ID
NCT05286762

About CTx-1301-Dexmethylphenidate 12.5 mg (titration only) + CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose) + CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose) + CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose) + Placebo

CTx-1301-Dexmethylphenidate 12.5 mg (titration only) + CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose) + CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose) + CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose) + Placebo is a phase 3 stage product being developed by Cingulate for ADHD. The current trial status is completed. This product is registered under clinical trial identifier NCT05286762. Target conditions include ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type.

What happened to similar drugs?

10 of 20 similar drugs in ADHD were approved

Approved (10) Terminated (2) Active (10)
✅atomoxetineEli LillyApproved
✅Strattera (atomoxetine)Eli LillyApproved
✅Atomoxetine + placeboEli LillyApproved
✅Atomoxetine Hydrochloride + placeboEli LillyApproved
✅atomoxetine (Strattera)Eli LillyApproved
✅Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + PlaceboNovartisApproved
✅methylphenidate HCl ERCT + PlaceboPfizerApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05286762Phase 3Completed

Competing Products

20 competing products in ADHD

See all competitors
ProductCompanyStageHype Score
atomoxetineEli LillyApproved
39
Strattera (atomoxetine)Eli LillyApproved
43
Atomoxetine + placeboEli LillyApproved
43
Atomoxetine Hydrochloride + placeboEli LillyApproved
43
atomoxetine (Strattera)Eli LillyApproved
43
Atomoxetine + stimulants (any approved ADHD medication)Eli LillyPre-clinical
26
dasotraline + PlaceboSumitomo PharmaPhase 3
40
dasotralineSumitomo PharmaPhase 1
29
dasotraline 4mgSumitomo PharmaPhase 3
40
AZD1446 + AZD1446 + AZD1446 + PlaceboAstraZenecaPhase 2
35
Placebo + AZD3480 + AZD3480AstraZenecaPhase 2
35
MK0249 + Concerta (methylphenidate) + PlaceboMerckPhase 2
35
Focalin XRNovartisPhase 3
40
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + PlaceboNovartisApproved
43
Dexmethylphenidate HCl extended-release capsulesNovartisPhase 3
40
Methylphenidate hydrochlorideNovartisPhase 3
40
Focalin XRNovartisPhase 3
40
methylphenidate HCl ERCT + PlaceboPfizerApproved
35
methylphenidate HCl ERCTPfizerApproved
35
Very Low Dose Quillivant XR + Low Dose Quillivant XR + Moderate Dose Quillivant XRPfizerApproved
43